Key Takeaways
- • HealthEquity (HQY) stock traded near $96 as of early September 2026, fluctuating within a $95.57–$97.41 intraday range, with a 52-week trading band of $72.76–$107.62, reflecting significant volatility despite proximity to the $100 level cited in the headline.
- • The company posted record adjusted EBITDA margin, record accounts, and record HSA assets for Q2 fiscal 2027, while raising full-year guidance, signaling strong operational execution in the health savings account administrator space.
- • HealthEquity reported adjusted earnings of $1.24 per share for Q2 FY2027, beating Zacks consensus estimates, with trailing twelve-month diluted EPS of $2.77 and a trailing P/E ratio of 33.64.
- • Market capitalization stands at approximately $7.95 billion based on 82.72 million shares outstanding, with Deutsche Bank raising its price target from $135 to $142 as of August 31, 2026, maintaining a Buy rating.
- • Levered free cash flow reached $397.51 million on trailing twelve-month basis, with total cash of $256 million and a total debt-to-equity ratio of 48.79%, indicating solid cash generation supporting potential shareholder returns or strategic investments.
Summary
HealthEquity (HQY) held near the $96 level in early September 2026, trading within a modest intraday range of $95.57–$97.41 following a prior close of $93.36. The stock's proximity to $100 reflects recovery from earlier weakness, though volatility has characterized the name throughout 2026, with the 52-week range spanning from $72.76 to $107.62. Market capitalization currently stands at $7.95 billion based on 82.72 million shares outstanding, positioning the company as a significant player in the health savings account administration sector.
Recent operational results provided support for the valuation. HealthEquity reported adjusted earnings of $1.24 per share for the second quarter of fiscal 2027, beating Zacks consensus expectations. The company posted record adjusted EBITDA margin alongside record accounts and record HSA assets, while simultaneously raising full-year guidance—a combination that typically attracts institutional capital. Trailing twelve-month diluted EPS reached $2.77, with net income available to common shareholders of $236.49 million on trailing revenue of $1.36 billion, reflecting a profit margin of 17.36%.
The financial profile demonstrates healthy cash generation and manageable leverage. Levered free cash flow on a trailing basis totaled $397.51 million, while the company maintained $256 million in total cash against a total debt-to-equity ratio of 48.79%. These metrics suggest the balance sheet supports both operational flexibility and potential capital allocation strategies. The analyst community remains constructive, with Deutsche Bank maintaining a Buy rating and raising its price target from $135 to $142 as of August 31, 2026, implying 48–50% upside from prevailing levels. The consensus 1-year target estimate stands at $119.
Trading metrics indicate moderate institutional interest with average daily volume of 868,011 shares and a beta of 0.22, suggesting defensive characteristics relative to broad market volatility. The trailing P/E ratio of 33.64 reflects premium valuation typical of high-quality healthcare administrators with recurring revenue models and strong growth trajectories in the HSA market.
Recent operational results provided support for the valuation. HealthEquity reported adjusted earnings of $1.24 per share for the second quarter of fiscal 2027, beating Zacks consensus expectations. The company posted record adjusted EBITDA margin alongside record accounts and record HSA assets, while simultaneously raising full-year guidance—a combination that typically attracts institutional capital. Trailing twelve-month diluted EPS reached $2.77, with net income available to common shareholders of $236.49 million on trailing revenue of $1.36 billion, reflecting a profit margin of 17.36%.
The financial profile demonstrates healthy cash generation and manageable leverage. Levered free cash flow on a trailing basis totaled $397.51 million, while the company maintained $256 million in total cash against a total debt-to-equity ratio of 48.79%. These metrics suggest the balance sheet supports both operational flexibility and potential capital allocation strategies. The analyst community remains constructive, with Deutsche Bank maintaining a Buy rating and raising its price target from $135 to $142 as of August 31, 2026, implying 48–50% upside from prevailing levels. The consensus 1-year target estimate stands at $119.
Trading metrics indicate moderate institutional interest with average daily volume of 868,011 shares and a beta of 0.22, suggesting defensive characteristics relative to broad market volatility. The trailing P/E ratio of 33.64 reflects premium valuation typical of high-quality healthcare administrators with recurring revenue models and strong growth trajectories in the HSA market.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.